Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
Open accessThe DOI matches its Crossref record; 170 of the 172 references it cites were found in a registry or an index.
Abstract
Over the past 30 years, the majority of (pre)clinical efforts to find an effective therapy for Alzheimer’s disease (AD) focused on clearing the β-amyloid peptide (Aβ) from the brain since, according to the amyloid cascade hypothesis, the peptide was (and it is still considered by many) the pathogenic determinant of this neurodegenerative disorder. However, as reviewed in this article, results from the numerous clinical trials that have tested anti-Aβ therapies to date indicate that this peptide plays a minor role in the pathogenesis of AD. Indeed, even Aducanumab and Lecanemab, the two antibodies recently approved by the FDA for AD therapy, as well as Donanemab showed limited efficacy on cognitive parameters in phase III clinical trials, despite their capability of markedly lowering Aβ brain load. Furthermore, preclinical evidence demonstrates that Aβ possesses several physiological functions, including memory formation, suggesting that AD may in part be due to a loss of function of this peptide. Finally, it is generally accepted that AD could be the result of many molecular dysfunctions, and therefore, if we keep chasing only Aβ, it means that we cannot see the forest for the trees.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These findings suggest that Aβ deposition or plaque formation might not be the actual cause of the disease, but rather a result or secondary factor of the pathological process.77,148”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [77]
Experimental — accuracy not yet measuredIn the citing paper
“According to the amyloid cascade hypothesis, tau protein tangles and neuroinflammation are brought on by Aβ aggregation, which in turn leads to neuronal death and cognitive decline [90,91,92].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“In 1992, this view culminated in the formulation of the original version of the amyloid cascade hypothesis (ACH) by Hardy and Higgins [12].”
BackgroundThe amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Lecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126 · cited 8×
“On the contrary, what is not controversial is the observation that there is no widespread frank neuronal death, and no neurofibrillary tangles (NTFs) are present in the vast majority of transgenic murine models of FAD.”
BackgroundInfluentialVassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“Aducanumab is a human monoclonal antibody selectively targeting different forms of aggregated Aβ, which, like gantenerumab, shows preferred binding to fibrils over protofibrils and has low affinity for Aβ monomers [61,82].”
BackgroundDonanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., et al. (2023) · JAMA · doi:10.1001/jama.2023.13239 · Cited by 2,932
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194
Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 2×
“In the first two trials (studies 301 and 302), the modified intention-to-treat population included 1090 carriers and 1114 non-carriers [50].”
BackgroundDefeating Alzheimer's disease and other dementias: a priority for European science and society
Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · cited 3×
“Phase III, randomised, double-blind, placebo-controlled (EXPEDITION 1, 2) 80 weeks [54] Mild to moderate AD ADAS-Cog11 and ADCS-ADL Significant small effects for ADCS-ADL only in EXPEDITION 2 Significant small effects in a secondary analysis on the pooled mild AD-population [55] Significant increase in plasma and CSF…”
BackgroundMethodAmyloid β Protein Gene: cDNA, mRNA Distribution, and Genetic Linkage Near the Alzheimer Locus
Tanzi, R. E., Gusella, J. F., Watkins, P. C., Bruns, G. A. P., St George-Hyslop, P., Van Keuren, M. L., Patterson, D., Pagan, S., Kurnit, D. M., & Neve, R. L. (1987) · Science · doi:10.1126/science.2949367 · Cited by 1,611
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 1×
“Results of another 6-year followup study on AN1972 showed that progression to severe AD stages was not prevented in immunised patients, and there was no evidence of improved survival despite a reduction of the Aβ load [44].”
BackgroundCleavage of Amyloid β Peptide During Constitutive Processing of Its Precursor
Esch, F. S., Keim, P. S., Beattie, E. C., Blacher, R. W., Culwell, A. R., Oltersdorf, T., McClure, D., & Ward, P. J. (1990) · Science · doi:10.1126/science.2111583 · Cited by 1,410
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
Budd Haeberlein, S., Aisen, P. S., Barkhof, F., Chalkias, S., Chen, T., Cohen, S., Dent, G., Hansson, O., Harrison, K., von Hehn, C., et al. (2022) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2022.30 · Cited by 1,367
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
Amyloid-β and tau--a toxic pas de deux in Alzheimer’s disease
Ittner, L. M., & Götz, J. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2967 · Cited by 1,269
Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049 · cited 2×
“Phase III, randomised, double-blind, placebo-controlled (EXPEDITION 3) 76 weeks [56] Mild AD ADAS-Cog11 No significant effects Significant increase in plasma and CSF No significant effects No significant effects”
BackgroundHaass, C., Koo, E. H., Mellon, A., Hung, A. Y., & Selkoe, D. J. (1992) · Nature · doi:10.1038/357500a0 · Cited by 899
Evidence that β-Amyloid Protein in Alzheimer's Disease Is Not Derived by Normal Processing
Sisodia, S. S., Koo, E. H., Beyreuther, K., Unterbeck, A., & Price, D. L. (1990) · Science · doi:10.1126/science.1691865 · Cited by 893
The case for rejecting the amyloid cascade hypothesis
Herrup, K. (2015) · Nature Neuroscience · doi:10.1038/nn.4017 · Cited by 768
Picomolar Amyloid-β Positively Modulates Synaptic Plasticity and Memory in Hippocampus
Puzzo, D., Privitera, L., Leznik, E., Fà, M., Staniszewski, A., Palmeri, A., & Arancio, O. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2692-08.2008 · Cited by 740
Ramsden, M., Kotilinek, L., Forster, C., Paulson, J., McGowan, E., SantaCruz, K., Guimaraes, A., Yue, M., Lewis, J., Carlson, G., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3279-05.2005 · Cited by 702 · cited 1×
“However, NTFs, neurodegeneration, and memory deficits are also present in murine models with only the expression of the mutated hMAPT gene, indicating that Aβ does not seem necessary for tau-induced neuropathological alterations but can enhance them [39,41].”
BackgroundCellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide
Haass, C., & Selkoe, D. J. (1993) · Cell · doi:10.1016/0092-8674(93)90312-e · Cited by 686
Risk factors for Alzheimer’s disease
A. Armstrong, R. (2019) · Folia Neuropathologica · doi:10.5114/fn.2019.85929 · Cited by 606
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
for the SCarlet RoAD Investigators, Ostrowitzki, S., Lasser, R. A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., Ashford, E., Retout, S., Hofmann, C., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0318-y · Cited by 567 · cited 3×
“A further exploratory analysis was performed by applying the algorithm of an AD progression model to identify individuals predicted to be fast or slow progressors in the population of patients with prodromal AD [62,64].”
MethodThe Alzheimer's disease Beta-secretase enzyme, BACE1
Cole, S. L., & Vassar, R. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-22 · Cited by 550
Laird, F. M., Cai, H., Savonenko, A. V., Farah, M. H., He, K., Melnikova, T., Wen, H., Chiang, H.-C., Xu, G., Koliatsos, V. E., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2766-05.2005 · Cited by 521
Symptom onset in autosomal dominant Alzheimer disease: A systematic review and meta-analysis
Ryman, D. C., Acosta-Baena, N., Aisen, P. S., Bird, T., Danek, A., Fox, N. C., Goate, A., Frommelt, P., Ghetti, B., Langbaum, J. B. S., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000596 · Cited by 502
Amyloid β Protein Enhances the Survival of Hippocampal Neurons in Vitro
Whitson, J. S., Selkoe, D. J., & Cotman, C. W. (1989) · Science · doi:10.1126/science.2928783 · Cited by 470
Bohrmann, B., Baumann, K., Benz, J., Gerber, F., Huber, W., Knoflach, F., Messer, J., Oroszlan, K., Rauchenberger, R., Richter, W. F., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110977 · Cited by 448 · cited 1×
“The antibody recognises both N-terminal and central regions of the peptide and induces its removal by Fc receptor-mediated microglial phagocytosis [59,60].”
BackgroundA Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
DeMattos, R. B., Lu, J., Tang, Y., Racke, M. M., DeLong, C. A., Tzaferis, J. A., Hole, J. T., Forster, B. M., McDonnell, P. C., Liu, F., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.10.029 · Cited by 442
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
Ostrowitzki, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.1538 · Cited by 431 · cited 1×
“The antibody recognises both N-terminal and central regions of the peptide and induces its removal by Fc receptor-mediated microglial phagocytosis [59,60].”
BackgroundTrial of solanezumab in preclinical Alzheimer's disease
Sperling, R. A., Donohue, M. C., Raman, R., Rafii, M. S., Johnson, K., Masters, C. L., van Dyck, C. H., Iwatsubo, T., Marshall, G. A., Yaari, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2305032 · Cited by 429 · cited 2×
“The A4 study was a randomised, double-blind, placebo-controlled phase III trial that enrolled preclinical AD individuals who were cognitively normal at baseline (CDR = 0; MMSE = 25–30; Wechsler Memory Scale Logical Memory Delayed Recall, LMDR = 6–18) and presented elevated amyloid levels, as assessed by amyloid-PET im…”
BackgroundMethodSöderberg, L., Johannesson, M., Nygren, P., Laudon, H., Eriksson, F., Osswald, G., Möller, C., & Lannfelt, L. (2023) · Neurotherapeutics · doi:10.1007/s13311-022-01308-6 · Cited by 427
β-Amyloid Monomers Are Neuroprotective
Giuffrida, M. L., Caraci, F., Pignataro, B., Cataldo, S., De Bona, P., Bruno, V., Molinaro, G., Pappalardo, G., Messina, A., Palmigiano, A., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.1736-09.2009 · Cited by 421
Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics
Hampel, H., Elhage, A., Cho, M., Apostolova, L. G., Nicoll, J. A. R., & Atri, A. (2023) · Brain · doi:10.1093/brain/awad188 · Cited by 412
The two faces of protein misfolding: gain‐ and loss‐of‐function in neurodegenerative diseases
Winklhofer, K. F., Tatzelt, J., & Haass, C. (2008) · The EMBO Journal · doi:10.1038/sj.emboj.7601930 · Cited by 401
Cirrito, J. R., May, P. C., O'Dell, M. A., Taylor, J. W., Parsadanian, M., Cramer, J. W., Audia, J. E., Nissen, J. S., Bales, K. R., Paul, S. M., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08844.2003 · Cited by 394
Sun, L., Zhou, R., Yang, G., & Shi, Y. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618657114 · Cited by 382
The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind
Ricciarelli, R., & Fedele, E. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170116143743 · Cited by 380
Self-citationPhase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
Siemers, E. R., Sundell, K. L., Carlson, C., Case, M., Sethuraman, G., Liu‐Seifert, H., Dowsett, S. A., Pontecorvo, M. J., Dean, R. A., & Demattos, R. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.06.1893 · Cited by 370 · cited 2×
“Phase III, randomised, double-blind, placebo-controlled (EXPEDITION 1, 2) 80 weeks [54] Mild to moderate AD ADAS-Cog11 and ADCS-ADL Significant small effects for ADCS-ADL only in EXPEDITION 2 Significant small effects in a secondary analysis on the pooled mild AD-population [55] Significant increase in plasma and CSF…”
MethodResultA trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease
Salloway, S., Farlow, M., McDade, E., Clifford, D. B., Wang, G., Llibre-Guerra, J. J., Hitchcock, J. M., Mills, S. L., Santacruz, A. M., Aschenbrenner, A. J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01369-8 · Cited by 359
Alzheimer’s Disease: An Updated Overview of Its Genetics
Andrade-Guerrero, J., Santiago-Balmaseda, A., Jeronimo-Aguilar, P., Vargas-Rodríguez, I., Cadena-Suárez, A. R., Sánchez-Garibay, C., Pozo-Molina, G., Méndez-Catalá, C. F., Cardenas-Aguayo, M.-D.-C., Diaz-Cintra, S., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043754 · Cited by 336
Adolfsson, O., Pihlgren, M., Toni, N., Varisco, Y., Buccarello, A. L., Antoniello, K., Lohmann, S., Piorkowska, K., Gafner, V., Atwal, J. K., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.4742-11.2012 · Cited by 317
Winblad, B., Andreasen, N., Minthon, L., Floesser, A., Imbert, G., Dumortier, T., Maguire, R. P., Blennow, K., Lundmark, J., Staufenbiel, M., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70140-0 · Cited by 310
Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Vandenberghe, R., Rinne, J. O., Boada, M., Katayama, S., Scheltens, P., Vellas, B., Tuchman, M., Gass, A., Fiebach, J. B., Hill, D., et al. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0189-7 · Cited by 304
The amyloid cascade hypothesis: an updated critical review
Kepp, K. P., Robakis, N. K., Høilund-Carlsen, P. F., Sensi, S. L., & Vissel, B. (2023) · Brain · doi:10.1093/brain/awad159 · Cited by 284
Amyloid-Independent Mechanisms in Alzheimer's Disease Pathogenesis
Pimplikar, S. W., Nixon, R. A., Robakis, N. K., Shen, J., & Tsai, L.-H. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4305-10.2010 · Cited by 281
Endogenous amyloid‐β is necessary for hippocampal synaptic plasticity and memory
Puzzo, D., Privitera, L., Fa', M., Staniszewski, A., Hashimoto, G., Aziz, F., Sakurai, M., Ribe, E. M., Troy, C. M., Mercken, M., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22313 · Cited by 278
Tucker, S., Möller, C., Tegerstedt, K., Lord, A., Laudon, H., Sjödahl, J., Söderberg, L., Spens, E., Sahlin, C., Waara, E. R., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-140741 · Cited by 272 · cited 1×
“Lecanemab is a humanised IgG1 antibody targeting soluble Aβ oligomers and showing some preference for fibrils over protofibrils [61,103].”
BackgroundRobakis, N., Wisniewski, H., Jenkins, E., Devine-Gage, E., Houck, G., Yao, X.-L., Ramakrishna, N., Wolfe, G., Silverman, W., & Ted Brown, W. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91754-5 · Cited by 268
The Production of Amyloid β Peptide Is a Critical Requirement for the Viability of Central Neurons
Plant, L. D., Boyle, J. P., Smith, I. F., Peers, C., & Pearson, H. A. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-13-05531.2003 · Cited by 266
Acosta-Baena, N., Sepulveda-Falla, D., Lopera-Gómez, C. M., Jaramillo-Elorza, M. C., Moreno, S., Aguirre-Acevedo, D. C., Saldarriaga, A., & Lopera, F. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70323-9 · Cited by 263
Genetics of familial and sporadic Alzheimer s disease
Piaceri, I. (2013) · Frontiers in Bioscience · doi:10.2741/e605 · Cited by 256
Vellas, B., Black, R., Thal, L., Fox, N., Daniels, M., McLennan, G., Tompkins, C., Leibman, C., Pomfret, M., & Grundman, M. (2009) · Current Alzheimer Research · doi:10.2174/156720509787602852 · Cited by 255
Fleisher, A. S., Chen, K., Quiroz, Y. T., Jakimovich, L. J., Gomez, M. G., Langois, C. M., Langbaum, J. B., Ayutyanont, N., Roontiva, A., Thiyyagura, P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70227-2 · Cited by 242
Neurogenic Effect of -Amyloid Peptide in the Development of Neural Stem Cells
Lopez-Toledano, M. A. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.0974-04.2004 · Cited by 241
Ryan, N. S., Nicholas, J. M., Weston, P. S. J., Liang, Y., Lashley, T., Guerreiro, R., Adamson, G., Kenny, J., Beck, J., Chavez-Gutierrez, L., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30193-4 · Cited by 239
Ostrowitzki, S., Bittner, T., Sink, K. M., Mackey, H., Rabe, C., Honig, L. S., Cassetta, E., Woodward, M., Boada, M., van Dyck, C. H., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.2909 · Cited by 229
Drachman, D. A. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.11.003 · Cited by 224
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
Cummings, J., Aisen, P., Lemere, C., Atri, A., Sabbagh, M., & Salloway, S. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00838-z · Cited by 224
Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells
Anderson, J. P., Esch, F. S., Keim, P. S., Sambamurti, K., Lieberburg, I., & Robakis, N. K. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90775-o · Cited by 213
Morris, G. P., Clark, I. A., & Vissel, B. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1918-8 · Cited by 212
Klein, G., Delmar, P., Voyle, N., Rehal, S., Hofmann, C., Abi-Saab, D., Andjelkovic, M., Ristic, S., Wang, G., Bateman, R., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0559-z · Cited by 212 · cited 4×
“However, exploratory analyses of change from baseline to year 2 for some clinical endpoints (CDR-SB, ADAS-Cog11, and MMSE) were performed on completers and suggested a tendency for slower clinical decline at higher amyloid removal by gantenerumab [65].”
MethodInfluentialAccelerated Brain Volume Loss Caused by Anti–β-Amyloid Drugs: A Systematic Review and Meta-analysis
Alves, F., Kalinowski, P., & Ayton, S. (2023) · Neurology · doi:10.1212/wnl.0000000000207156 · Cited by 212
Amyloid-β and τ serve antioxidant functions in the aging and Alzheimer brain
Smith, M. A., Casadesus, G., Joseph, J. A., & Perry, G. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)01021-3 · Cited by 189
Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
Vaz, M., Silva, V., Monteiro, C., & Silvestre, S. (2022) · Clinical Interventions in Aging · doi:10.2147/cia.s325026 · Cited by 183
Lecanemab in Early Alzheimer’s Disease
(2023) · New England Journal of Medicine · doi:10.1056/nejmc2301380 · Cited by 172
Amyloid beta mediates memory formation
Garcia-Osta, A., & Alberini, C. M. (2009) · Learning & Memory · doi:10.1101/lm.1310209 · Cited by 171
Barakos, J., Purcell, D., Suhy, J., Chalkias, S., Burkett, P., Grassi, C. M., Castrillo-Viguera, C., Rubino, I., & Vijverberg, E. (2022) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2022.21 · Cited by 165
Revisiting FDA Approval of Aducanumab
Alexander, G. C., Knopman, D. S., Emerson, S. S., Ovbiagele, B., Kryscio, R. J., Perlmutter, J. S., & Kesselheim, A. S. (2021) · New England Journal of Medicine · doi:10.1056/nejmp2110468 · Cited by 162
The γ-Secretase Complex: Membrane-Embedded Proteolytic Ensemble
Wolfe, M. S. (2006) · Biochemistry · doi:10.1021/bi060799c · Cited by 161
Amyloid β protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease
Tamaoka, A., Sawamura, N., Fukushima, T., Shoji, S., Matsubara, E., Shoji, M., Hirai, S., Furiya, Y., Endoh, R., & Mori, H. (1997) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(96)00314-0 · Cited by 157
Controversy and Progress in Alzheimer’s Disease — FDA Approval of Aducanumab
Rabinovici, G. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmp2111320 · Cited by 155
Amyloid-β 11 C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials
Liu, E., Schmidt, M. E., Margolin, R., Sperling, R., Koeppe, R., Mason, N. S., Klunk, W. E., Mathis, C. A., Salloway, S., Fox, N. C., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001877 · Cited by 151 · cited 2×
“Phase III, randomised, double-blind, placebo-controlled 78 weeks [50,51] Mild to moderate AD, APOE ε4 carriers and non-carriers ADAS-cog11 and DAD No significant effects in the whole population ND Significant effects in carriers No significant effects”
BackgroundPharmacological Inhibition of BACE1 Impairs Synaptic Plasticity and Cognitive Functions
Filser, S., Ovsepian, S. V., Masana, M., Blázquez‐Llorca, L., Elvang, A. B., Volbracht, C., Müller, M. B., Jung, C. K. E., & Herms, J. W. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.10.013 · Cited by 149
Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease
Farlow, M. R., Andreasen, N., Riviere, M.-E., Vostiar, I., Vitaliti, A., Sovago, J., Caputo, A., Winblad, B., & Graf, A. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0108-3 · Cited by 144
Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study
Vandenberghe, R., Riviere, M., Caputo, A., Sovago, J., Maguire, R. P., Farlow, M., Marotta, G., Sanchez‐Valle, R., Scheltens, P., Ryan, J. M., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.12.003 · Cited by 141
A Physiological Role for Amyloid-β Protein: Enhancement of Learning and Memory
Morley, J. E., Farr, S. A., Banks, W. A., Johnson, S. N., Yamada, K. A., & Xu, L. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1230 · Cited by 141
Giedraitis, V., Sundelöf, J. E., Irizarry, M. C., Gårevik, N., Hyman, B. T., Wahlund, L., Ingelsson, M., & Lannfelt, L. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.09.023 · Cited by 137
Making the final cut: Pathogenic amyloid-β peptide generation by γ-secretase
Steiner, H., Fukumori, A., Tagami, S., & Okochi, M. (2018) · Cell Stress · doi:10.15698/cst2018.11.162 · Cited by 133
Tariot, P. N., Lopera, F., Langbaum, J. B., Thomas, R. G., Hendrix, S., Schneider, L. S., Rios‐Romenets, S., Giraldo, M., Acosta, N., Tobon, C., et al. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.02.002 · Cited by 128 · cited 2×
“Phase II, randomised, double-blind, placebo-controlled (API ADAD Colombia) 5 to 8 years Terminated early [76,80,81] Cognitively healthy Colombian family APICC No significant effects Stable levels/significant increase in CSF No significant effects No significant effects”
BackgroundSturchio, A., Dwivedi, A. K., Young, C. B., Malm, T., Marsili, L., Sharma, J. S., Mahajan, A., Hill, E. J., Andaloussi, S. E., Poston, K. L., et al. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.100988 · Cited by 128
Alzheimer’s disease due to loss of function: A new synthesis of the available data
Kepp, K. P. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.06.004 · Cited by 124
Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin
Ultsch, M., Li, B., Maurer, T., Mathieu, M., Adolfsson, O., Muhs, A., Pfeifer, A., Pihlgren, M., Bainbridge, T. W., Reichelt, M., et al. (2016) · Scientific Reports · doi:10.1038/srep39374 · Cited by 124 · cited 1×
“Crenezumab is a humanised monoclonal immunoglobulin G4 antibody that binds different forms of Aβ, including monomers, oligomers, and fibrils, although it shows a higher affinity for oligomeric Aβ [73,74].”
BackgroundOn the origin of Alzheimer's disease. Trials and tribulations of the amyloid hypothesis
Castello, M. A., & Soriano, S. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.10.001 · Cited by 122
Treatments for Alzheimer's disease emerge
Selkoe, D. J. (2021) · Science · doi:10.1126/science.abi6401 · Cited by 117
Lopez Lopez, C., Tariot, P. N., Caputo, A., Langbaum, J. B., Liu, F., Riviere, M., Langlois, C., Rouzade‐Dominguez, M., Zalesak, M., Hendrix, S., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.02.005 · Cited by 116 · cited 1×
“The study will assess vaccine safety and efficacy to slow progression or even prevent onset of AD in cognitively healthy subjects at high risk for the development of clinical AD, based on their age, APOE genetics, and elevation of brain amyloid [48].”
BackgroundEmerging risk of environmental factors: insight mechanisms of Alzheimer’s diseases.
Rahman, M. A., Rahman, M. S., Uddin, M. J., Mamum-Or-Rashid, A. N. M., Pang, M.-G., & Rhim, H. (2020) · Environmental Science and Pollution Research · doi:10.1007/s11356-020-08243-z · Cited by 115
The need to show minimum clinically important differences in Alzheimer's disease trials
Liu, K. Y., Schneider, L. S., & Howard, R. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00197-8 · Cited by 113
Rodríguez-Giraldo, M., González-Reyes, R. E., Ramírez-Guerrero, S., Bonilla-Trilleras, C. E., Guardo-Maya, S., & Nava-Mesa, M. O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113630 · Cited by 111
Multi-Targets: An Unconventional Drug Development Strategy for Alzheimer’s Disease
Gong, C.-X., Dai, C.-L., Liu, F., & Iqbal, K. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.837649 · Cited by 106
Can we learn lessons from the FDA's approval of aducanumab?
Liu, K. Y., & Howard, R. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00557-x · Cited by 104
Pasquier, F., Sadowsky, C., Holstein, A., Leterme, G. L. P., Peng, Y., Jackson, N., Fox, N. C., Ketter, N., Liu, E., Ryan, J. M., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150376 · Cited by 102
Rao, R. V., Subramaniam, K. G., Gregory, J., Bredesen, A. L., Coward, C., Okada, S., Kelly, L., & Bredesen, D. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021659 · Cited by 102
Lecanemab for Alzheimer's disease: tempering hype and hope
Lancet, T. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02480-1 · Cited by 101
Gulisano, W., Melone, M., Ripoli, C., Tropea, M. R., Li Puma, D. D., Giunta, S., Cocco, S., Marcotulli, D., Origlia, N., Palmeri, A., et al. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.0163-19.2019 · Cited by 100
The Monomer State of Beta-Amyloid: Where the Alzheimer's Disease Protein Meets Physiology
Giuffrida, M. L., Caraci, F., De Bona, P., Pappalardo, G., Nicoletti, F., Rizzarelli, E., & Copani, A. (2010) · Reviews in the Neurosciences · doi:10.1515/revneuro.2010.21.2.83 · Cited by 91
Lecanemab (Leqembi) is not the right drug for patients with Alzheimer’s disease
Kurkinen, M. T. (2023) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/171379 · Cited by 90
The state versus amyloid-β: the trial of the most wanted criminal in Alzheimer disease
Rottkamp, C. A., Atwood, C., Joseph, J. A., Nunomura, A., Perry, G. L., & Smith, M. A. (2002) · Peptides · doi:10.1016/s0196-9781(02)00069-4 · Cited by 87
Role of common and rare APP DNA sequence variants in Alzheimer disease
Hooli, B. V., Mohapatra, G., Mattheisen, M., Parrado, A. R., Roehr, J. T., Shen, Y., Gusella, J. F., Moir, R., Saunders, A. J., Lange, C., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182515972 · Cited by 87
Step by step: towards a better understanding of the genetic architecture of Alzheimer’s disease
Lambert, J.-C., Ramirez, A., Grenier-Boley, B., & Bellenguez, C. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02076-1 · Cited by 87
Quintela-López, T., Ortiz-Sanz, C., Serrano-Regal, M. P., Gaminde-Blasco, A., Valero, J., Baleriola, J., Sánchez-Gómez, M. V., Matute, C., & Alberdi, E. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1636-8 · Cited by 80
Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease
Rabinovici, G. D., & La Joie, R. (2023) · JAMA · doi:10.1001/jama.2023.11703 · Cited by 80
Amyloid-β Peptide Is Needed for cGMP-Induced Long-Term Potentiation and Memory
Palmeri, A., Ricciarelli, R., Gulisano, W., Rivera, D., Rebosio, C., Calcagno, E., Tropea, M. R., Conti, S., Das, U., Roy, S., et al. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.3607-16.2017 · Cited by 79
Self-citationLecanemab for Alzheimer’s disease
Walsh, S., Merrick, R., Richard, E., Nurock, S., & Brayne, C. (2022) · BMJ · doi:10.1136/bmj.o3010 · Cited by 76
cAMP, cGMP and Amyloid β: Three Ideal Partners for Memory Formation
Ricciarelli, R., & Fedele, E. (2018) · Trends in Neurosciences · doi:10.1016/j.tins.2018.02.001 · Cited by 74
Self-citationThe complex pathway between amyloid β and cognition: implications for therapy
Jagust, W. J., Teunissen, C. E., & DeCarli, C. S. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00128-x · Cited by 74
Aducanumab—Hope or Disappointment for Alzheimer’s Disease
Wojtunik-Kulesza, K., Rudkowska, M., & Orzeł-Sajdłowska, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054367 · Cited by 73
Lecanemab: Looking Before We Leap
Burke, J. F., Kerber, K. A., Langa, K. M., Albin, R. L., & Kotagal, V. (2023) · Neurology · doi:10.1212/wnl.0000000000207505 · Cited by 69
Goldgaber, D., Lerman, M. I., McBride, W. O., Saffiotti, U., & Gajdusek, D. C. (1987) · PubMed · Cited by 67
The amyloid precursor protein: a converging point in Alzheimer’s disease
Delport, A., & Hewer, R. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02863-x · Cited by 67
Qu, L., Li, Y., Liu, F., Fang, Y., He, J., Ma, J., Xu, T., Wang, L., Lei, P., Dong, H., et al. (2023) · Aging and Disease · doi:10.14336/ad.2023.0823-2 · Cited by 67
Genetic Phenotypes of Alzheimer’s Disease: Mechanisms and Potential Therapy
Quan, M., Cao, S., Wang, Q., Wang, S., & Jia, J. (2023) · Phenomics · doi:10.1007/s43657-023-00098-x · Cited by 66
Physiological Roles of Monomeric Amyloid-β and Implications for Alzheimer’s Disease Therapeutics
Jeong, H., Shin, H., Hong, S., & Kim, Y. S. (2022) · Experimental Neurobiology · doi:10.5607/en22004 · Cited by 65
Donanemab for Alzheimer Disease—Who Benefits and Who Is Harmed?
Manly, J. J., & Deters, K. (2023) · JAMA · doi:10.1001/jama.2023.11704 · Cited by 63
β-amyloid-(1–40) increases long-term potentiation in rat hippocampus in vitro
Wu, J., Anwyl, R., & Rowan, M. J. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00539-w · Cited by 60
Klein, G., Delmar, P., Kerchner, G. A., Hofmann, C., Abi-Saab, D., Davis, A., Voyle, N., Baudler, M., Fontoura, P., & Doody, R. (2021) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2020.68 · Cited by 60
Madhu, P., & Mukhopadhyay, S. (2021) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30141 · Cited by 59
Amyloid Precursor Protein: A Regulatory Hub in Alzheimer's Disease
Chen, J., Chen, J.-S., Li, S., Zhang, F., Deng, J., Zeng, L., & Tan, J. (2023) · Aging and Disease · doi:10.14336/ad.2023.0308 · Cited by 59
Delor, I., Charoin, J., Gieschke, R., Retout, S., Jacqmin, P., & Initiative, F. T. A. D. N. (2013) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.54 · Cited by 58
L., K., Ng, T. K. S., Wee, H. N., & Ching, J. (2023) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2023.111787 · Cited by 58
What Is the “Relevant” Amyloid β42 Concentration?
Raskatov, J. A. (2019) · ChemBioChem · doi:10.1002/cbic.201900097 · Cited by 57
Sturchio, A., (DIAN), T. D. I. A. C., Dwivedi, A. K., Malm, T., Wood, M. J. A., Cilia, R., Sharma, J. S., Hill, E. J., Schneider, L. S., Graff-Radford, N. R., et al. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-220808 · Cited by 57
Hypothesis review: Alzheimer's overture guidelines
Ferrer, I. (2022) · Brain Pathology · doi:10.1111/bpa.13122 · Cited by 57
The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes
Kepp, K. P., Sensi, S. L., Johnsen, K. B., Barrio, J. R., Høilund-Carlsen, P. F., Neve, R. L., Alavi, A., Herrup, K., Perry, G., Robakis, N. K., et al. (2023) · Journal of Alzheimer's Disease · doi:10.3233/jad-230099 · Cited by 53
Three FDA advisory panel members resign over approval of Alzheimer’s drug
Mahase, E. (2021) · BMJ · doi:10.1136/bmj.n1503 · Cited by 48
Soluble Amyloid-β Consumption in Alzheimer’s Disease
Espay, A. J., Sturchio, A., Schneider, L. S., & Ezzat, K. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-210415 · Cited by 45
Fagiani, F., Lanni, C., Racchi, M., & Govoni, S. M. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.635880 · Cited by 44
Rujeedawa, T., Félez, E. C., Clare, I. C. H., Fortea, J., Strydom, A., Rebillat, A., Coppus, A. M. W., Levin, J., & Zaman, S. H. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194582 · Cited by 44
Cognitive changes in the preclinical phase of familial Alzheimer's disease
Arango-Lasprilla, J. C., Cuetos, F., Valencia, C., Uribe, C., & Lopera, F. (2007) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803390601174151 · Cited by 41
Ushering in a New Era of Alzheimer Disease Therapy
Widera, E., Brangman, S. A., & Chin, N. A. (2023) · JAMA · doi:10.1001/jama.2023.11701 · Cited by 40
Ivanoiu, A., Pariente, J., Booth, K., Lobello, K., Luscan, G., Hua, L., Lucas, P., Styren, S., Yang, L., Li, D., et al. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0193-y · Cited by 39
Early Effects of Aβ Oligomers on Dendritic Spine Dynamics and Arborization in Hippocampal Neurons
Ortiz-Sanz, C., Gaminde-Blasco, A., Valero, J., Bakota, L., Brandt, R., Zugaza, J. L., Matute, C., & Alberdi, E. (2020) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2020.00002 · Cited by 38
A novel mechanism for cyclic adenosine monophosphate–mediated memory formation: Role of amyloid beta
Ricciarelli, R., Puzzo, D., Bruno, O., Canepa, E., Gardella, E., Rivera, D., Privitera, L., Domenicotti, C., Marengo, B., Marinari, U. M., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24130 · Cited by 34
Self-citationAducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease
Salloway, S., & Cummings, J. (2021) · Neurology · doi:10.1212/wnl.0000000000012451 · Cited by 34
The underexplored question of β-amyloid monomers
Copani, A. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.057 · Cited by 33
Mannix, R. C., Zhang, J., Park, J., Lee, C., & Whalen, M. J. (2011) · Journal of Neurotrauma · doi:10.1089/neu.2011.1759 · Cited by 32
Aducanumab Trials EMERGE But Don't ENGAGE
Schneider, L. S. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.37 · Cited by 32
An insider's perspective on FDA approval of aducanumab
Wang, Y. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12382 · Cited by 31
Inhibition of amyloid precursor protein secretases reduces recovery after spinal cord injury
Pajoohesh-Ganji, A., Burns, M. P., Pal-Ghosh, S., Tadvalkar, G., Hokenbury, N. G., Stepp, M. A., & Faden, A. I. (2014) · Brain Research · doi:10.1016/j.brainres.2014.02.049 · Cited by 29
Beta-amyloid short- and long-term synaptic entanglement
Lanni, C., Fagiani, F., Racchi, M., Preda, S., Pascale, A., Grilli, M., Allegri, N., & Govoni, S. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.018 · Cited by 29
Canepa, E., Domenicotti, C., Marengo, B., Passalacqua, M., Marinari, U. M., Pronzato, M. A., Fedele, E., & Ricciarelli, R. (2013) · IUBMB Life · doi:10.1002/iub.1109 · Cited by 28
Self-citationAmyloid β: Walking on the dark side of the moon
Fedele, E., Rivera, D., Marengo, B., Pronzato, M. A., & Ricciarelli, R. (2015) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2015.09.001 · Cited by 27
Self-citationExogenous Aβ1-42 monomers improve synaptic and cognitive function in Alzheimer's disease model mice
Duan, Y., Lv, J., Zhang, Z., Chen, Z., Wu, H., Chen, J., Chen, Z., Yang, J., Wang, D., Liu, Y., et al. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109002 · Cited by 27
Ulaganathan, S., & Pitchaimani, A. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121918 · Cited by 25
Increased Cerebrospinal Fluid Aβ38/Aβ42 Ratio in Alzheimer Disease
Mehta, P. D., & Pirttila, T. (2005) · Neurodegenerative Diseases · doi:10.1159/000090363 · Cited by 24
Imbimbo, B. P., Ippati, S., & Watling, M. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1793755 · Cited by 21
Araki, W. (2023) · Cells · doi:10.3390/cells12101386 · Cited by 20
Lecanemab trial finds slight slowing of cognitive decline, but clinical benefits are uncertain
Mahase, E. (2022) · BMJ · doi:10.1136/bmj.o2912 · Cited by 19
Holdridge, K. C., Yaari, R., Hoban, D. B., Andersen, S., & Sims, J. R. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13031 · Cited by 19
Critical thinking of Alzheimer’s transgenic mouse model: current research and future perspective
Li, X., Quan, M., Wei, Y., Wang, W., Xu, L., Wang, Q., & Jia, J. (2023) · Science China Life Sciences · doi:10.1007/s11427-022-2357-x · Cited by 16
Alzheimer's drug approved despite murky results
Servick, K. (2021) · Science · doi:10.1126/science.372.6547.1141 · Cited by 15
Forest, K. H., Taketa, R., Arora, K., Todorovic, C., & Nichols, R. A. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.576038 · Cited by 13
Lecanemab: turning point, or status quo? An ethics perspective
Daly, T. P. (2023) · Brain · doi:10.1093/brain/awad094 · Cited by 13
Lantz, M. J., Roberts, A. M., Delgado, D. D., & Nichols, R. A. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02807-9 · Cited by 13
Investigating the amyloid-beta enhancing effect of cGMP in neuro2a cells
Calcagno, E., Caudano, F., Passalacqua, M., Pronzato, M. A., Fedele, E., & Ricciarelli, R. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2017.08.001 · Cited by 10
Self-citationAβ oligomers: role at the synapse
Puzzo, D. (2019) · Aging · doi:10.18632/aging.101818 · Cited by 9
Donanemab leads to modest slowing of Alzheimer’s progression, study finds
Iacobucci, G. (2023) · BMJ · doi:10.1136/bmj.p1659 · Cited by 7
Reply: Lecanemab: turning point, or status quo? An ethics perspective
Hardy, J., & Mummery, C. J. (2023) · Brain · doi:10.1093/brain/awad102 · Cited by 4
Rizk, J. G., & Lewin, J. C. (2022) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2022-111914 · Cited by 3
Morley (2010) · doi:10.3233/jad-2009-1230
Research works printed but not linked: 6
- (2023, August 25). Gantenerumab Mystery: How Did It Lose Potency in Phase 3?. Available online: https://www.alzforum.org/news/conference-coverage/gantenerumab-mystery-how-did-it-lose-potency-phase-3.
- (2023, August 29). Alzforum.Org API ADAD Columbia Trial Reported Results. Available online: https://www.alzforum.org/news/conference-coverage/crenezumab-secondaries-negative-gantenerumab-ole-hints-efficacy.
- Brenman, 2023, Lecanemab in Early Alzheimer’s Disease, N. Engl. J. Med., 388, 1631
- Valenzuela, 2023, Lecanemab in Early Alzheimer’s Disease, N. Engl. J. Med., 388, 1630, 10.1056/NEJMc2301380 · DOI · Paper page
- Sabbagh, 2023, Response: Lecanemab in Early Alzheimer’s Disease, N. Engl. J. Med., 388, 1631
- Zeng, 2023, Lecanemab in Early Alzheimer’s Disease, N. Engl. J. Med., 388, 1630, 10.1056/NEJMc2301380 · DOI · Paper page
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“The toxicity mechanism of A β aggregates remains uncertain, but different perspectives exist: 77,128 A β might cause AD pathology through the loss of physiological functions during the aggregation process.”
BackgroundRecent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56
Li, X., Wu, Z., Si, X., Li, J., Wu, G., & Wang, M. (2025) · European journal of medical research · doi:10.1186/s40001-025-02699-w · Cited by 52
Systemic inflammation as a central player in the initiation and development of Alzheimer’s disease
Bayraktaroğlu, I., Ortí-Casañ, N., Dam, D. V., Deyn, P. P. D., & Eisel, U. L. M. (2025) · Immunity & Ageing · doi:10.1186/s12979-025-00529-5 · Cited by 53
Kazemeini, S., Nadeem-Tariq, A., Shih, R., Rafanan, J., Ghani, N., & Vida, T. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111720 · Cited by 41
“…such as Aducanumab and Lecanemab show limited e ff ectiveness in reducing A β load without translating into signi fi cant cognitive improvements [43]. does not always This failure has led to growing skepticism about the hypothesis, prompting the exploration of alternative models and approaches…”
Background
Metadata
- Authors
- Fedele, E.
- Affiliations
- Ospedale Policlinico San Martino (IT)
- Corresponding author
- Fedele, Ernesto
- ORCID
- Fedele, Ernesto
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-09-24
- Volume
- 24
- Issue
- 19
- Pages
- 14499
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10578107
- OpenAlex
- W4386996842
- Cited by
- 102
- References
- 172
- Citations by year
- 2026: 28 · 2025: 47 · 2024: 26 · 2023: 1
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion, other-oa)
- Funders
- The University of Genoa
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, anti-amyloid therapy, amyloid hypothesis, amyloid-beta, aducanumab, lecanemab, donanemab, memory formation, amyloid pathogenesis, clinical trial efficacy
- MeSH terms
- Alzheimer Disease, Amyloid, Brain, Humans, Amyloid beta-Peptides, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.